Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L; CESAME Study Group..

Aliment Pharmacol Ther. 2017 Feb;45(4):533-541. doi: 10.1111/apt.13897. Epub 2016 Dec 19.

PMID:
27995656
2.

Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L; CESAME study group..

Aliment Pharmacol Ther. 2016 Jan;43(2):252-61. doi: 10.1111/apt.13466. Epub 2015 Nov 9.

PMID:
26549003
3.

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group..

Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25.

PMID:
24162591
4.

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group..

Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23.

PMID:
22271569
5.

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group..

Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25.

PMID:
21708105
6.

Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations.

Pariente A, Lahmek P, Duprat C, Denis J, Faroux R, Renou C, Nalet B, Morin T, Cadranel JF; Investigator Group belonging to Association Nationale des Gastroentérologues des Hôpitaux Généraux (ANGH)..

Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1297-302.

PMID:
20964260
7.

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group..

Lancet. 2009 Nov 7;374(9701):1617-25. doi: 10.1016/S0140-6736(09)61302-7.

PMID:
19837455
8.

[Diagnosis of spontaneous ascites infection in patients with cirrhosis: reagent strips].

Wisniewski B, Rautou PE, Al Sirafi Y, Lambare-Narcy B, Drouhin F, Constantini D, Fischer D, Labayle D, Denis J.

Presse Med. 2005 Aug 27;34(14):997-1000. French.

PMID:
16225251
9.

[Presence of anti-Yersinia pseudotuberculosis agglutinins during a flare-up of ileal Crohn's disease. Apropos of 3 cases].

Delchier JC, Constantini D, Soulé JC.

Gastroenterol Clin Biol. 1983 Jun-Jul;7(6-7):580-4. French.

PMID:
6873577

Supplemental Content

Loading ...
Support Center